Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Olutasidenib

Review the clinical trials studying olutasidenib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-9 of 9

Study of Olutasidenib and Temozolomide in HGG
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Olutasidenib for the Treatment of Patients with IDH1-Mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olutasidenib in Combination with Hypomethylation Therapy for the Treatment of IDH1-Mutated Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olutasidenib Combined with Co-targeted Therapy for the Treatment of Myeloid Cell Cancers in Patients with IDH1 and Co-signaling Gene Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olutasidenib, Venetoclax, and Azacitidine for the Treatment of Newly Diagnosed IDH1 Mutated Acute Myeloid Leukemia
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Olutasidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, or Chronic Myelomonocytic Leukemia after Transplant
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine and Venetoclax in Combination with Olutasidenib for the Treatment of Patients with Newly Diagnosed, Recurrent or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olutasidenib for the Treatment of Patients with IDH1 Mutated AML, MDS or CMML after Donor Hematopoietic Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
Status: Active
Location: 300 locations